Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Exclusion Criteria

• •Superficial thrombophlebitis that is within 3 cm from the sapheno-femoral junction,
• •deep vein thrombosis on ultrasound exam, deep vein thrombosis or pulmonary embolism within last 6 months, treatment for cancer during last 6 months,
• •anticoagulant medication for more than 48 hours prior to inclusion,
• •need for oral non-steroidal anti-inflammatory drugs during the study, significant bleeding event during past month,
• •major surgery within last 3 months, low platelet count (below 100×109/L),
• •kidney disease (Calculated creatinine clearance \< 30 mL/min), woman of child-bearing potential not using reliable contraceptive method